TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended December 31, 2012 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number,] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T18:46:56+00:00 February 14th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] SC 13G: (Original Filing)

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By | 2016-03-27T18:47:54+00:00 February 14th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] SC 13G: for a reporting persons initial filing on this

[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]

By | 2016-03-27T18:49:46+00:00 February 14th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] POS AM: Post Effective Amendment No.4 to FORM S-1 REGISTRATION

[Post Effective Amendment No.4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang Chief Executive Officer Tianyin Pharmaceutical Co.,] [HUNTER TAUBMAN WEISS LLP 17 State Street, Suite 2000 New York, New York 10007 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com December 7, 2012 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: In so acting, we have examined and relied upon the originals or] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 4 to a Registration Statement on Form S-1 pertaining to the registration of 15,784,640 shares of]

By | 2016-03-27T18:55:22+00:00 December 7th, 2012|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[TPI Reports First Quarter Fiscal Year 2013 Financial Results CHENGDU, China, Nov. 15, 2012 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal year 2013. First Quarter of Fiscal Year 2013 Ended] [Tianyin Pharmaceutical Co., Inc. (“TPI”) First Quarter of Fiscal Year 2013 Earnings Call November 15, 2012 8:30 AM ET Operator James Tong TPI First quarter of fiscal year 2013 ended September 30, 2012, financial highlights: revenue was $16 million compared with $17.5 million in first quarter of fiscal year 2012 (“FIQ 2012”). Operating income was $2.2 million compared with $2.1] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 15, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:56:42+00:00 November 23rd, 2012|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports First Quarter Fiscal Year 2013 Financial

[TPI Reports First Quarter Fiscal Year 2013 Financial Results CHENGDU, China, Nov. 15, 2012 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal year 2013. First Quarter of Fiscal Year 2013 Ended] [Tianyin Pharmaceutical Co., Inc. (“TPI”) First Quarter of Fiscal Year 2013 Earnings Call November 15, 2012 8:30 AM ET Operator James Tong TPI First quarter of fiscal year 2013 ended September 30, 2012, financial highlights: revenue was $16 million compared with $17.5 million in first quarter of fiscal year 2012 (“FIQ 2012”). Operating income was $2.2 million compared with $2.1] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 15, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:58:35+00:00 November 23rd, 2012|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x For the quarterly period ended September 30, 2012 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number,] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Guoqing Jiang Chief Executive Officer, Chief Accounting Officer & Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T18:59:55+00:00 November 14th, 2012|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended September 30, 2012 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number,] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2012 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Guoqing Jiang Chief Executive Officer, Chief Accounting Officer & Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T19:00:46+00:00 November 14th, 2012|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] CORRESP: (Original Filing)

[Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 November 2, 2012 Division of Corporate Finance Attn: Jeffrey Riedler Re: Post-Effective Amendment No. 1 Registration Statement on Form S-1 Filed March 27, 2012 Post-Effective Amendment No. 2 Registration Statement on Form S-1 Filed June 13, 2012 Post-Effective Amendment]

By | 2016-03-27T19:04:54+00:00 November 2nd, 2012|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] CORRESP: Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo

[Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 November 2, 2012 Division of Corporate Finance Attn: Jeffrey Riedler Re: Post-Effective Amendment No. 1 Registration Statement on Form S-1 Filed March 27, 2012 Post-Effective Amendment No. 2 Registration Statement on Form S-1 Filed June 13, 2012 Post-Effective Amendment]

By | 2016-03-27T19:06:01+00:00 November 2nd, 2012|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar